In An Organic Compound Patents (Class 424/1.65)
-
Patent number: 11542267Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.Type: GrantFiled: June 12, 2020Date of Patent: January 3, 2023Assignees: Australian Nuclear Science and Technology Organisation, The Australian National UniversityInventors: Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
-
Patent number: 11478558Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.Type: GrantFiled: May 30, 2018Date of Patent: October 25, 2022Assignee: The Johns Hopkins UniversityInventors: Sangeeta Ray, Martin G. Pomper
-
Patent number: 11452785Abstract: In general, the patent herein is a radioactive chemical which attaches to the virus and releases radiation which kills the virus. Specifically, the chemical is an alpha-ketoamide designed to attach to the virus. However, instead of 2 bromine atoms, Iodine-131 is at the location of where the bromine atoms would have been. Iodine-131 is a radioactive element which releases ionizing radiation. The virus with which this radioactive chemical is designed for is the COVID-19 coronavirus, although the patent is for any virus. Since, modifications can be made in chemical structure and radioactive chemical species, the patent is for any and all chemicals which contain any type of radioactive element to kill or disrupt any type of virus.Type: GrantFiled: June 5, 2020Date of Patent: September 27, 2022Inventor: Zachary Charles Crouch
-
Patent number: 11413360Abstract: The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.Type: GrantFiled: July 30, 2018Date of Patent: August 16, 2022Assignees: Technische Universität München, Technische Universität München—Klinikum Rechts der IsarInventors: Alexander Josef Wurzer, Hans-Jürgen Wester, Matthias Johannes Eiber
-
Patent number: 11406723Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.Type: GrantFiled: September 18, 2019Date of Patent: August 9, 2022Inventors: David Morse, Robert Gillies, Mark Mclaughlin, Thaddeus Wadas, Hyun Joo Kil, Narges Tafreshi
-
Patent number: 11400057Abstract: The present invention relates to methods of treating female reproductive tract irritation (such as pain and pruritus) or/and inflammation.Type: GrantFiled: October 2, 2019Date of Patent: August 2, 2022Assignee: University of RochesterInventors: David Foster, Megan L. Falsetta Wood, Richard P. Phipps
-
Patent number: 11384106Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18(F18) radioisotope, or other radionuclide.Type: GrantFiled: March 18, 2020Date of Patent: July 12, 2022Assignee: Emory UniversityInventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
-
Patent number: 11285244Abstract: The invention relates to a method for preparing a polymer scaffold that comprises the steps of providing a piece of a fabric of filaments of a first biodegradable or biocompatible polymer, applying a coating of a second polymer to said arrangement of filaments, and stretching the piece along its axis of longitudinal extension, thereby obtaining an aligned microfibrillar scaffold. The invention further relates to a method for providing an artificial tissue, and to a microfibrillar scaffold of aligned filaments obtained by the method of the invention.Type: GrantFiled: October 27, 2017Date of Patent: March 29, 2022Assignees: ETH ZÜRICH, UNIVERSITÄT ZÜRICHInventors: Simon Philipp Hoerstrup, Seyedvahid Hosseini, Viola Vogel
-
Patent number: 11285223Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.Type: GrantFiled: November 26, 2018Date of Patent: March 29, 2022Assignee: MediBeacon Inc.Inventors: Richard B. Dorshow, Steven J. Hanley, Phillip I. Tarr
-
Patent number: 11266739Abstract: Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration.Type: GrantFiled: December 3, 2015Date of Patent: March 8, 2022Assignee: Juno Therapeutics, Inc.Inventor: Mark J. Gilbert
-
Patent number: 11167048Abstract: Disclosed are compositions and methods relating to prostate cancer. In particular, disclosed are bivalent targeting ligands that specifically bind prostate specific membrane antigen and gastrin-releasing peptide receptor. Bivalent binding agents disclosed herein can be used to image a tissue in a subject in need thereof and to diagnose prostate cancer in a subject in need thereof. Bivalent binding agents disclosed herein can be used to treat prostate cancer in a subject in need thereof.Type: GrantFiled: December 13, 2019Date of Patent: November 9, 2021Assignee: The Curators of the University of MissouriInventors: Charles Jeffrey Smith, Rajendra Prasad Bandari
-
Patent number: 11111243Abstract: The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: GrantFiled: June 7, 2018Date of Patent: September 7, 2021Assignee: Global Blood Therapeutics, Inc.Inventors: Chul Yu, Ming Yu, Manuel Zancanella, Zhe Li
-
Patent number: 11077110Abstract: Provided herein are compositions and methods for treating or preventing metabolic disorders. In particular, provided herein are compositions, methods, and uses of Cyclin-dependent Kinase 6 (CDK6) inhibitors for treating and preventing metabolic diseases (e.g., type II diabetes, obesity, metabolic syndrome, elevated blood pressure, cardiovascular diseases, elevated fasting plasma glucose, and high serum triglycerides).Type: GrantFiled: March 17, 2017Date of Patent: August 3, 2021Assignee: Tufts Medical CenterInventor: Miaofen G. Hu
-
Patent number: 11071714Abstract: Compositions comprising polymers comprising one or more ketal, monothioketal, and/or thioketal bonds are provided, as well as related methods and kits. In some embodiments, a polymer may comprise one or more repeat units comprising one or more ketal, monothioketal, and/or thioketal bonds and a precursor of a pharmaceutically active agent. The precursor of the pharmaceutically active agent may be located in the backbone or may be a pendant group. The polymer may degrade in certain environments (e.g., aqueous environments, acidic environments, in vivo, etc.) to produce the pharmaceutically active agent and other biocompatible degradation products, such as certain ketones, alcohols, and/or thiols. Regardless of the location of the precursor of the pharmaceutically active agent in the repeat unit(s), the polymer may have a prolonged degradation time and/or release of the pharmaceutically active agent in certain environments.Type: GrantFiled: April 28, 2017Date of Patent: July 27, 2021Assignee: Children's Medical Center CorporationInventors: Daniel S. Kohane, Shutao Guo
-
Patent number: 11065349Abstract: This invention provides a class of dual mode imaging tracer capable of acting both as a fluorescent imaging tracer and a positron emission tomography imaging tracer. Tracers in accordance with this invention generally have a fluorescent core with a boron-fluoride element embedded therein. Exemplary embodiments of the tracer include 18F-labeled BODIPY compounds and derivative thereof. Also provided are tracer kits containing a sterile formulation of a BODIPY dye either in a radio-labeled or pre-labeled state, and methods for imaging heart perfusion using the 18F-labeled dual mode tracers.Type: GrantFiled: March 15, 2013Date of Patent: July 20, 2021Inventors: Peter S. Conti, Zibo Li, Shuanglong Liu, Dan Li
-
Patent number: 11045564Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).Type: GrantFiled: August 26, 2019Date of Patent: June 29, 2021Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
-
Patent number: 11027029Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.Type: GrantFiled: November 9, 2016Date of Patent: June 8, 2021Assignee: Cellbion Co., LtdInventors: Jae Min Jeong, Sung-Hyun Moon, Yun-Sang Lee
-
Patent number: 11020493Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.Type: GrantFiled: July 25, 2019Date of Patent: June 1, 2021Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
-
Patent number: 10980901Abstract: The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.Type: GrantFiled: December 15, 2016Date of Patent: April 20, 2021Assignees: The European Atomic Energy Community (EURATOM), Represented by the European Commission, Universität HeidelbergInventors: Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis, Uwe Haberkorn, Frederik Giesel, Clemens Kratochwil
-
Patent number: 10968245Abstract: The invention provides a method for preparing a technetium-99m tricarbonyl intermediate. The method comprises reacting a manganese carbonyl compound used as a carbon monoxide source with pertechnetate and water to obtain the technetium-99m tricarbonyl intermediate. The method for preparing a technetium-99m tricarbonyl intermediate in an embodiment of the invention can complete the preparation of the intermediate at atmospheric pressure and room temperature. The method is easy to operate, uses easily obtained raw materials, has a high labeling yield, and can be used to prepare various types of technetium tricarbonyl labeled probes.Type: GrantFiled: December 28, 2016Date of Patent: April 6, 2021Assignee: Institute of High Energy Physics, Chinese Academy of SciencesInventors: Wenjiang Yang, Yu Liu, Jingquan Xue, Yanhua Zhang
-
Patent number: 10910123Abstract: Methods for isolating Pb and/or Pb isotopes from various sources are provided. Compositions comprising Pb and/or Pb isotopes free of certain amounts of various contaminants are also provided.Type: GrantFiled: December 20, 2018Date of Patent: February 2, 2021Assignee: Lantheus Medical Imaging, Inc.Inventor: Keith R. Olewine
-
Patent number: 10898594Abstract: PAMAM dendrimer based CEST imaging agents, pharmaceutical compositions comprising the same and methods of uses thereof are disclosed.Type: GrantFiled: October 27, 2016Date of Patent: January 26, 2021Assignee: The Johns Hopkins UniversityInventors: Wojciech Lesniak, Sridhar Nimmagadda, Nikita Oskolkov, Michael McMahon, Xiaolei Song, Martin G. Pomper
-
Patent number: 10870629Abstract: The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron emission tomography (PET).Type: GrantFiled: June 18, 2018Date of Patent: December 22, 2020Assignee: FUTURECHEM CO., LTD.Inventors: Dae Yoon Chi, Byoung Se Lee, So Young Chu, Woon Jung Jung, Hyeon Jin Jeong, Min Hwan Kim, Mi Hyun Kim, Kyo Chul Lee, Yong Jin Lee, Ji Ae Park, Ran Ji Yoo, Sang Moo Lim
-
Patent number: 10835624Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.Type: GrantFiled: July 21, 2017Date of Patent: November 17, 2020Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SAInventors: Heiko Kroth, Jérôme Molette, Vincent Darmency, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden, Emanuele Gabellieri
-
Patent number: 10802094Abstract: Systems and methods for magnetic resonance imaging (“MRI”) of multiple different nuclear spin species using the same radio frequency (“RF”) coil are described. Generally, multiple different nuclear spin species are imaged using the same RF coil by using an MRI system whose magnetic field can be rapidly ramped between a number of different, and arbitrary, magnetic field strengths. The magnetic field of this MRI system can be ramped to different values in reasonable amounts of time (e.g., in a time frame that is feasible within an imaging study).Type: GrantFiled: May 27, 2016Date of Patent: October 13, 2020Assignee: SYNAPTIVE MEDICAL (BARBADOS) INC.Inventor: Jeff A. Stainsby
-
Patent number: 10765748Abstract: In various aspects, embodiments of the present invention are directed to a series of multivalent dendrons containing a bioactive peptide domain and surface-binding catechol domains. In some embodiments, these multivalent dendrons were obtained through solid phase synthesis and have a strong binding affinity to metal oxide surfaces such as, TiO2, ZrO2, CeO2, and Fe3O4, SiO2, as well as other inorganic surfaces such as hydroxyapatite, silver, fluorapatite, calcium carbonate and gold. These catechol-bearing dendrons provide a fast and efficient method to functionalize a wide range of inorganic materials with bioactive peptides and have the potential to be used in coating orthopaedic implants and fixation devices.Type: GrantFiled: July 13, 2015Date of Patent: September 8, 2020Assignee: University of AkronInventors: Matthew Becker, Wen Tang
-
Patent number: 10758635Abstract: The present invention relates to 99mTc-maraciclatide radiopharmaceutical compositions, which are stabilised with a radioprotectant. Also described are kits for the preparation of the radiopharmaceutical compositions, as well methods of preparing such compositions from the kit. The invention also includes methods of imaging the mammalian body using the radiopharmaceutical compositions.Type: GrantFiled: July 27, 2011Date of Patent: September 1, 2020Assignee: Serac Healthcare LimitedInventor: David Jonathan Barnett
-
Patent number: 10744211Abstract: The invention provides a novel trifunctional targeting construct and related compositions and methods that are useful in therapeutic, diagnostic (including imaging) of various biological and/or pathological conditions and diseases such as cancers and diabetes. The trifunctional targeting construct of the invention provides enhanced clearing step and reduced non-specific background via complete clearance of undesired antibody conjugates.Type: GrantFiled: March 28, 2018Date of Patent: August 18, 2020Assignee: University of MassachusettsInventors: Guozheng Liu, Shuping Dou
-
Patent number: 10744214Abstract: The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. The methods described herein are able to diagnose, treat and/or monitor the therapy of numerous diseases and conditions including atherosclerosis, atherothrombosis, cerebral vascular disease, cerebral ischemia, cerebral infarct and meningitis as well as pneumonitis, pericarditis, multiple sclerosis, lupus erythematosus and pancreatitis, among others.Type: GrantFiled: December 28, 2016Date of Patent: August 18, 2020Assignee: STC.UNMInventor: Jeffrey P. Norenberg
-
Patent number: 10717946Abstract: Methods for adjusting the solubility of a botanical oil in water, along with the resulting modified botanical oil and related products (e.g., treatment compositions, wipes, absorbent articles, etc.) are provided. In one embodiment, the method includes reacting the botanical oil to form a reactive product (e.g., having a hydroxyl group); and attaching a hydrophilic end group (e.g., a carboxylic acid, a carboxylic acid salt, a sugar, etc.) on the reactive product to form a modified botanical oil. The modified botanical oil generally, in most embodiments, has a greater solubility in water than the botanical oil (e.g., a solubility in water of about 10 grams per 100 grams of water or greater, such as completely soluble in water). The botanical oil includes, in one particular embodiment, an essential oil, such as those essential oil that include at least one terpene compound.Type: GrantFiled: December 27, 2012Date of Patent: July 21, 2020Assignee: Kimberly-Clark Worldside, Inc.Inventors: David William Koenig, Mary Kay Foegen, Corey Thomas Cunningham, Aimin He, Yang Huang
-
Patent number: 10688200Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 20, 2016Date of Patent: June 23, 2020Assignee: FIVE ELEVEN PHARMA INC.Inventors: Hank F. Kung, Karl Ploessl, Seok Rye Choi, Zhihao Zha, Zehui Wu
-
Patent number: 10660976Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.Type: GrantFiled: November 6, 2018Date of Patent: May 26, 2020Assignee: Washington UniversityInventor: Vijay Sharma
-
Patent number: 10646598Abstract: Disclosed is a class of versatile Sarcophagine based bifunctional chelators (BFCs) containing a hexa-aza cage for labeling with metals having either imaging, therapeutic or contrast applications radiolabeling and one or more linkers (A) and (B). The compounds have the general formula where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a thiol, an azide and an alkene. Also disclosed are conjugate of the BFC and a targeting moiety, which may be a peptide or antibody. Also disclosed are metal complexes of the BFC/targeting moiety conjugates that are useful as radiopharmaceuticals, imaging agents or contrast agents.Type: GrantFiled: June 27, 2016Date of Patent: May 12, 2020Assignee: University of Southern CaliforniaInventors: Peter S. Conti, Hancheng Cai, Zibo Li, Shuanglong Liu
-
Patent number: 10633404Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18 (F18) radioisotope, or other radionuclide.Type: GrantFiled: March 10, 2016Date of Patent: April 28, 2020Assignee: Emory UniversityInventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
-
Patent number: 10561379Abstract: The present invention concerns a positron emission tomography (PET) contrast agent or imaging tracer comprising a red blood cell (RBC) internally labeled with 2-deoxy-2-(18F)fluoro-D-glucose (FDG); a method of preparing RBCs of a human or non-human animal for PET, comprising labeling RBCs in vitro with FDG to produce FDG-labeled RBCs; a method for in vivo imaging of RBCs using PET, comprising: introducing RBCs internally labeled with FDG (FDG-RBCs) into the circulatory system of a human or non-human animal subject in vivo; and PET imaging the introduced FDG-RBCs in the subject; a composition useful for labeling RBCs, and a kit for labeling RBCs.Type: GrantFiled: January 11, 2017Date of Patent: February 18, 2020Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor: Jung Wook Choi
-
Patent number: 10537651Abstract: Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.Type: GrantFiled: September 29, 2016Date of Patent: January 21, 2020Assignee: Serene, LLCInventors: Nigel R. Stevenson, Jaime Simon, Gilbert R. Gonzales
-
Patent number: 10527942Abstract: In a preferred aspect, organic coating compositions, particularly antireflective coating compositions for use with an overcoated photoresist, are provided that comprise 1) one or more glycidyl groups; and 2) one or more aromatic groups that each comprises two or more substituents that comprise hydroxy, thiol and/or amine moieties. Catechol-containing polymers and methods for producing same also are provided.Type: GrantFiled: November 29, 2016Date of Patent: January 7, 2020Assignee: Rohm and Haas Electronics Materials Korea Ltd.Inventors: Jae Hwan Sim, Jung Kyu Jo, EunHye Cho, Hye-Won Lee, Jin Hong Park, Eui-Hyun Ryu, Jae-Bong Lim
-
Patent number: 10517848Abstract: Disclosed are compositions and methods for mitigating a tolerance effect from ingestion of cannabis-based medicines in human subjects, for example, subjects having an increased risk of unresponsiveness to one or more therapeutic agents such as, for example, antidepressants and antianxiety drugs. In some methods, the human subjects have been previously treated with one or more therapeutic agents such as, for example, antidepressants and antianxiety drugs, and have developed at least partial tolerance to the one or more therapeutic agents.Type: GrantFiled: August 27, 2018Date of Patent: December 31, 2019Inventor: Louis M. Segreti
-
Patent number: 10472338Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.Type: GrantFiled: October 17, 2016Date of Patent: November 12, 2019Assignees: GE HEALTHCARE LIMITED, NIHON MEDI-PHYSICS CO., LTD.Inventors: Yuki Okumura, Gota Tonoya, Tomoyuki Matsunami
-
Patent number: 10465165Abstract: The present invention provides a multifunctional 2-D and 3-D matrix for propagation of stem cells. In particular, a chitosan-based biomaterial scaffold is engineered to promote CNS regeneration from primitive neural precursors by stabilizing a recombinant protein, fibroblast growth factor to preserve the cardinal properties of stem cells. The matrix, is further modified by the addition of either the extracellular matrix protein fibronectin or the small peptide RGD or IKVAV. A method to manufacture an injectable multifunctional microsphere scaffold is also disclosed that is suitable as a vehicle for cell transplantation to repair traumatic brain injuries.Type: GrantFiled: January 28, 2014Date of Patent: November 5, 2019Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, NEW JERSEY INSTITUTE OF TECHNOLOGYInventors: Cheul Cho, Steven Levison, Nolan Skop, Frances Calderon, Chirag Gandhi
-
Patent number: 10441669Abstract: Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.Type: GrantFiled: October 6, 2014Date of Patent: October 15, 2019Assignee: ILLINOIS INSTITUTE OF TECHNOLOGYInventor: Hyun-Soon Chong
-
Patent number: 10434196Abstract: Disclosed herein are a multivalent saccharide complex, a radioactive multivalent saccharide complex contrast agent and use thereof. The multivalent saccharide complex has a chelator, a linker, and glucose, and is configured to diagnose and evaluate the therapeutic effect of cancers.Type: GrantFiled: February 2, 2018Date of Patent: October 8, 2019Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.CInventors: Hung-Man Yu, Wuu-Jyh Lin, Mei-Hui Wang, Chun-Hao Tseng
-
Patent number: 10406246Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.Type: GrantFiled: July 18, 2014Date of Patent: September 10, 2019Assignee: Deutsches KresbsforschungszentrumInventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
-
Patent number: 10398791Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).Type: GrantFiled: August 28, 2018Date of Patent: September 3, 2019Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
-
Patent number: 10377778Abstract: The present invention relates complexes comprising a PSMA targeting compound linked to a radionuclide, such as 212Pb or 227Th. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.Type: GrantFiled: December 13, 2018Date of Patent: August 13, 2019Assignee: Sciencons ASInventor: Roy Hartvig Larsen
-
Patent number: 10303846Abstract: A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.Type: GrantFiled: August 12, 2015Date of Patent: May 28, 2019Assignee: MeMed Diagnostics Ltd.Inventors: Eran Eden, Kfir Oved, Roy Navon, Assaf Cohen-Dotan, Olga Boico
-
Patent number: 10278657Abstract: A method for performing an imaging scan of a subject includes positioning a narrow field-of-view camera at a first imaging position to acquire a first set of imaging information of a first object of interest, positioning the narrow field-of-view camera at a second imaging position to acquire a second set of imaging information of a second object of interest, determining emission counts for the first and second sets of imaging information, and utilizing the determined emission counts to generate a value that indicates a probability of a successful medical procedure being performed on the subject.Type: GrantFiled: June 6, 2017Date of Patent: May 7, 2019Assignee: General Electric CompanyInventors: Aharon Peretz, Yaron Hefetz, Lana Volokh
-
Patent number: 10233277Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.Type: GrantFiled: March 4, 2013Date of Patent: March 19, 2019Assignee: The Governing Council of the University of TorontoInventors: Xiao Yu Wu, Alireza Shalviri, Ping Cai
-
Patent number: 10150804Abstract: Somatostatin derivative compounds of general formula (I) that may be readily labelled with the isotope fluorine-18 and that have affinity and selectivity for cellular somatostatin receptors are provided. The labelled compounds are useful clinically as radioactive tracers in various in vivo imaging applications (for example, using positron emission tomography (PET) and related techniques) to detect somatostatin-expressing cells and tissues, including tumors, or as therapeutic agents.Type: GrantFiled: January 2, 2015Date of Patent: December 11, 2018Assignees: BRITISH COLUMBIA CANCER AGENCY BRANCH, THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDUSTRY LIAISON OFFICEInventors: Francois Benard, Kuo-Shyan Lin, David Perrin, Zhibo Liu, Maral Pourghiasian
-
Patent number: 10071943Abstract: Copper-catalyzed radiofluorination of iodonium salts, iodonium salts, and compounds obtained by copper-catalyzed radiofluorination of iodonium salts are disclosed. Diagnostic and therapeutic methods involving such compounds also are disclosed.Type: GrantFiled: April 10, 2015Date of Patent: September 11, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Peter J. H. Scott, Melanie S. Sanford, Naoko Ichiishi, Allen F. Brooks, Melissa Rodnick, Joseph J. Topczewski